MCAM

Across TCGA pan-cancer cohorts, MCAM mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MCAM data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MCAM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MCAM expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where MCAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.950	1.000	.016	12	view →
HNSC	DFS	Tertile	All	0.844	0.717	.031	4	view →
LSCC	OS	Quartile	III,IV	0.928	0.476	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MCAM–LUAD (OS)

Open the LUAD breakdown →